Claim No. 2015 HCV 03627 ...

A recent blood-based hepatitis C virus assay on Nuclein's DASH system highlighted its on-device sample prep, among other features that have been driving its adoption.

The project is expected to generate direct employment for around 1,000 people and indirect employment for nearly 2,000 more, ...

Atea Pharmaceuticals (AVIR) will present the Company’s strategic priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco. Atea ended 2025 ...

People with hepatitis C virus who inject drugs could be evaluated for cure approximately 2 months earlier than current ...

In the past one month, Ashok Leyland has outperformed the market by surging 18 per cent, as compared to 1.3 per cent decline ...

Ambitiously aiming for a place in the global commercial vehicle elite, Ashok Leyland has launched its inaugural manufacturing ...

Housing Works, a premier housing organization dedicated to fostering stability and affordability in Central Oregon, announces ...

Atea Pharmaceuticals, Inc. Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.

Housing Works, a housing organization dedicated to fostering stability and affordability in Central Oregon, has announced ...

MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic ...